Hemodynamic effects of the antihypertensive treatment with atenolol plus chlortalidone in fixed combination: A double-blind crossover comparison with atenolol

B. Ricciardelli, A. Cuocolo, N. De Luca

Research output: Contribution to journalArticle

Abstract

Twenty patients with mild or moderate essential hypertension participated in a double-blind crossover randomized trial aimed at assessing, by echocardiography, the hemodynamic effects of the antihypertensive therapy with atenolol administered once daily (100 mg) alone or combined with chlortalidone (25 mg) in fixed combination. Blood pressure and heart rate were measured at rest and during bicycle exercise before and after four-week periods of treatment. Both atenolol and atenolol plus chlortalidone reduced significantly blood pressure and heart rate. The reduction in blood pressure was mediated by a reduction in cardiac output. However, the combined treatment was also able to prevent the increase in stroke volume observed after atenolol alone. Furthermore, the combined treatment was able to significantly lower blood pressure during exercise, while atenolol alone failed. These results suggest that the association of chlortalidone potentiates the antihypertensive effect of atenolol by acting through a different mechanism.

Original languageEnglish
Pages (from-to)901-911
Number of pages11
JournalCurrent Therapeutic Research
Volume37
Issue number5
Publication statusPublished - 1985

Fingerprint

Atenolol
Antihypertensive Agents
Hemodynamics
Chlorthalidone
Blood Pressure
Heart Rate
Exercise
Therapeutics
Cardiac Output
Stroke Volume
Cross-Over Studies
Echocardiography
chlortalidone drug combinations atenolol

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Hemodynamic effects of the antihypertensive treatment with atenolol plus chlortalidone in fixed combination : A double-blind crossover comparison with atenolol. / Ricciardelli, B.; Cuocolo, A.; De Luca, N.

In: Current Therapeutic Research, Vol. 37, No. 5, 1985, p. 901-911.

Research output: Contribution to journalArticle

@article{21547081a97a40a1a42cd1a71078f7b1,
title = "Hemodynamic effects of the antihypertensive treatment with atenolol plus chlortalidone in fixed combination: A double-blind crossover comparison with atenolol",
abstract = "Twenty patients with mild or moderate essential hypertension participated in a double-blind crossover randomized trial aimed at assessing, by echocardiography, the hemodynamic effects of the antihypertensive therapy with atenolol administered once daily (100 mg) alone or combined with chlortalidone (25 mg) in fixed combination. Blood pressure and heart rate were measured at rest and during bicycle exercise before and after four-week periods of treatment. Both atenolol and atenolol plus chlortalidone reduced significantly blood pressure and heart rate. The reduction in blood pressure was mediated by a reduction in cardiac output. However, the combined treatment was also able to prevent the increase in stroke volume observed after atenolol alone. Furthermore, the combined treatment was able to significantly lower blood pressure during exercise, while atenolol alone failed. These results suggest that the association of chlortalidone potentiates the antihypertensive effect of atenolol by acting through a different mechanism.",
author = "B. Ricciardelli and A. Cuocolo and {De Luca}, N.",
year = "1985",
language = "English",
volume = "37",
pages = "901--911",
journal = "Current Therapeutic Research - Clinical and Experimental",
issn = "0011-393X",
publisher = "Excerpta Medica",
number = "5",

}

TY - JOUR

T1 - Hemodynamic effects of the antihypertensive treatment with atenolol plus chlortalidone in fixed combination

T2 - A double-blind crossover comparison with atenolol

AU - Ricciardelli, B.

AU - Cuocolo, A.

AU - De Luca, N.

PY - 1985

Y1 - 1985

N2 - Twenty patients with mild or moderate essential hypertension participated in a double-blind crossover randomized trial aimed at assessing, by echocardiography, the hemodynamic effects of the antihypertensive therapy with atenolol administered once daily (100 mg) alone or combined with chlortalidone (25 mg) in fixed combination. Blood pressure and heart rate were measured at rest and during bicycle exercise before and after four-week periods of treatment. Both atenolol and atenolol plus chlortalidone reduced significantly blood pressure and heart rate. The reduction in blood pressure was mediated by a reduction in cardiac output. However, the combined treatment was also able to prevent the increase in stroke volume observed after atenolol alone. Furthermore, the combined treatment was able to significantly lower blood pressure during exercise, while atenolol alone failed. These results suggest that the association of chlortalidone potentiates the antihypertensive effect of atenolol by acting through a different mechanism.

AB - Twenty patients with mild or moderate essential hypertension participated in a double-blind crossover randomized trial aimed at assessing, by echocardiography, the hemodynamic effects of the antihypertensive therapy with atenolol administered once daily (100 mg) alone or combined with chlortalidone (25 mg) in fixed combination. Blood pressure and heart rate were measured at rest and during bicycle exercise before and after four-week periods of treatment. Both atenolol and atenolol plus chlortalidone reduced significantly blood pressure and heart rate. The reduction in blood pressure was mediated by a reduction in cardiac output. However, the combined treatment was also able to prevent the increase in stroke volume observed after atenolol alone. Furthermore, the combined treatment was able to significantly lower blood pressure during exercise, while atenolol alone failed. These results suggest that the association of chlortalidone potentiates the antihypertensive effect of atenolol by acting through a different mechanism.

UR - http://www.scopus.com/inward/record.url?scp=0021857473&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021857473&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0021857473

VL - 37

SP - 901

EP - 911

JO - Current Therapeutic Research - Clinical and Experimental

JF - Current Therapeutic Research - Clinical and Experimental

SN - 0011-393X

IS - 5

ER -